CDKN1B and urogenital neoplasm: We and others have demonstrated that although there are several mechanisms by which EGCG may modulate prostate carcinogenesis, the catechin-EGCG potently and selectively inhibits the proteasome activity in intact human cells and ultimately results in the accumulation of B-α and p27 proteins, and growth arrest [27–31].